L-dopa-induced peak-dose dyskinesias in patients with Parkinson's disease: A clinical pharmacologic approach

Movement Disorders

Volumn 14, Issue SUPPL. 1, 1999, Pages 19-32

  Rascol, Olivier ^a  

^a TOULOUSE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BUSPIRONE; DECAHYDRO 6 PHOSPHONOMETHYL 3 ISOQUINOLINECARBOXYLIC ACID; DEXTROMETHORPHAN; DIPRENORPHINE; DOPAMINE RECEPTOR; FLUOXETINE; GLUTAMIC ACID; IDAZOXAN; IFENPRODIL; LEVODOPA; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NALOXONE; NORADRENALIN; RECEPTOR SUBTYPE; RILUZOLE; RITANSERIN; SEROTONIN;

CLINICAL PHARMACOLOGY; CLINICAL TRIAL; CONFERENCE PAPER; DENERVATION; DRUG ELIMINATION; DRUG HALF LIFE; DYSKINESIA; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; MOTOR PERFORMANCE; PARKINSON DISEASE; PRIORITY JOURNAL;

ANTIPARKINSON AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DYSKINESIA, DRUG-INDUCED; GLUTAMIC ACID; HUMANS; LEVODOPA; NARCOTICS; NOREPINEPHRINE; PARKINSON DISEASE; RECEPTORS, DOPAMINE; SEROTONIN;

EID: 0032736042     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (152)

1. Prichard BNC, Turner P. Clinical pharmacology: function, organization, and training. Lancet 1971;7725:653-655.
2. Crout JR. A description of clinical pharmacology and the clinical pharmacologist. Clin Pharmacol Ther 1986;39:439.
3. World Health Organization. International Drug Monitoring. The Role of National Centers. Technical Report Series 498. Geneva: WHO, 1972.
4. Tanner C. Drug-induced movement disorders (tardive dyskinesia and L-dopa induced dyskinesia). In: Vinken PJ, Bruyn GW, Klawans HL, eds. Extrapyramidal Disorders. (Handbook of Clinical Neurology, vol 5) Amsterdam: Elsevier, 1996:185-204.
5. Bédard PJ, DiPaolo T, Falardeau P, Boucher R. Chronic treatment with levodopa but not bromocriptine induces dyskinesia in MPTP parkinsonian monkeys: correlations with [3H] spiperone binding. Brain Res 1986;379:294-299.
6. Crossman AR, Clarke CE, Boyce S, Robertson RG, Sambrook MA. MPTP-induced parkinsonism in the monkey: neurochemical pathology, complications of treatment and pathophysiological mechanisms. Can J Neurol Sci 1987;14:428-435.
7. Luquin MR, Scipioni O, Vaamonde J, Gershanik O, Obeso JA. Levodopa-induced dyskinesia in Parkinson's disease: clinical and pharmacological classification. Mov Disord 1992;7:117-124.
8. Marconi R, Lefebvre-Caparros D, Bonnet AM, Vidailhet M, Dubois B, Agid Y. Levodopa-induced dyskinesias in Parkinson's disease: phenomenology and pathophysiology. Mov Disord 1994; 9:2-12.
9. Goetz CG, Stebbins GT, Shale HM, et al. Utility of an objective dyskinesia rating scale for Parkinson's disease: inter- and intrarater reliability assessment. Mov Disord 1994;9:390-394.
10. Giron LT, Koller WC. Methods of managing levodopa-induced dyskinesias. Drug Safety 1996;14:365-374.
11. Poewe WH, Lees AJ, Stern GM. Dystonia in Parkinson's disease: clinical and pharmacological features. Ann Neurol 1988;23:73-78.
12. Marsden CD, Parkes JD, Quinn N. Fluctuations of disability in Parkinson's disease: clinical aspects. In: Marsden CD, Fahn S, eds. Movement Disorders. London: Butterworths, 1982:96-119.
13. Cotzias GC, Pappavasiliou PS, Gellene R. Modification of parkinsonism - chronic treatment with L-dopa. N Engl J Med 1969; 280:337-345.
14. Gomez-Mancilla B, Bédard P. Effect of chronic treatment with (+)-PHNO, a D-2 agonist in MPTP-treated monkeys. Exp Neurol 1992;117:185-188.
15. Luquin MR, Laguna J, Obeso JA. Selective D-2 receptor stimulation induces dyskinesia in parkinsonian monkeys. Ann Neurol 1992;31:551-554.
16. Markham CH. The choreoathetoid movement disorder induced by levodopa. Clin Pharmacol Ther 1971;12:340-343.
17. Mones RJ, Elizan TS, Siegel GJ. Analysis of L-dopa-induced dyskinesias in 51 patients with parkinsonism. J Neurol Neurosurg Psychiatry 1971;34:668-673.
18. Nutt JG. Levodopa-induced dyskinesia: review, observations, and speculations. Neurology 1990;40:340-345.
19. Harwood G, Hierous R, Fletcher NA, Marsden CD. Lesions from a remarkable family with dopa-responsive dystonia. J Neurol Neurosurg Psychiatry 1994;57:460-463.
20. Nygaard TG, Marsden CD, Fahn S. Dopa-responsive dystonia: long-term treatment response and prognosis. Neurology 1992;41: 174-181.
21. Wenning GK, Ben Shlomo Y, Magalhães M, Daniel SE, Quinn NP. Clinicopathological study of 35 cases of multiple system atrophy. J Neurol Neurosurg Psychiatry 1995;58:160-166.
22. Wenning GK, Tison F, Ben Shlomo Y, Daniel SE, Quinn NP. Multiple system atrophy: a review of 203 pathologically proven cases. Mov Disord 1997;12:133-147.
23. Duvoisin RC, Lobo-Antunes J, Yahr MD. Response of patients with postencephalitic parkinsonism to levodopa, J Neurol Neurosurg Psychiatry 1972;35:487-495.
24. Sacks O. Awakenings. New York, NY: Harper Perennial, 1990.
25. Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983;219:979-980.
26. Ballard PA, Tetrud JW, Langston JW. Permanent human parkinsonism due to 1-menthyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): seven cases. Neurology 1985;35:949-956.
27. Blanchette P, Bédard PJ, Matsumura PJ, Richard H, Filion M. Pathophysiology of levodopa-induced dyskinesia: changing concepts. In: Percheron G, ed. The Basal Ganglia. New York, NY: Plenum Press, 1994:539-548.
28. Bergman KJ, Mendoza MR, Yahr MD. Parkinson's disease and long-term levodopa therapy. Adv Neurol 1986;45:463-467.
29. Horstink MWIM, Zijlmans JCM, Pasman JW, Berger HJC, Van'tHof MA. Severity of Parkinson's disease is a risk factor for peak-dose dyskinesia. J Neurol Neurosurg Psychiatry 1990;53: 224-226.
30. Schneider JS. Levodopa-induced dyskinesias in parkinsonian monkeys: relationship to extent of nigrostriatal damage. Pharmacol Biochem Behav 1989;34:193-196.
31. Boyce S, Rupniak NMJ, Steventon MJ, Iversen SD. Nigrostriatal damage is required for induction of dyskinesias by L-dopa in squirrel monkeys. Clin Neuropharmacol 1990;13:448-458.
32. Bédard PJ, Gomez-Mancilla B, Blanchette P, Gagnon C, Di Paolo T. Levodopa-induced dyskinesias: facts and fancy. What does the MPTP monkey model tell us? Can J Neurol Sci 1992;19:134-137.
33. Graneras AK, Carlsson A, Svanborg A. The aging neuron: influence on symptomatology and response in Parkinson's disease. Adv Neurol 1979;24:327-334.
34. Rajput AH, Stern W, Laverty WH. Chronic low dose of levodopa therapy in Parkinson's disease: an argument for delaying levodopa therapy. Neurology 1984;34:991-996.
35. Nutt JG, Woodward WR, Carter JH, Gancher ST. Effect of long-term therapy on the pharmacodynamics of levodopa: relation to the on-off phenomenon. Arch Neurol 1992;49:1123-1130.
36. Nutt JG, Woodward WR. Levodopa pharmacokinetics and pharmacodynamics in fluctuating parkinsonian patients. Neurology 1986;36:739-744.
37. Blin J, Bonnet AM, Agid Y. Does levodopa aggravate Parkinson's disease? Neurology 1988;38:1410-1416.
38. Montastruc JL, Rascol O, Senard JM, Rascol A. A randomized controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow up. J Neurol Neurosurg Psychiatry 1994;57:1034-1038.
39. Rinne UK, Brocco F, Chouza C, et al. Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. Drugs 1998;55:S23-S30.
40. Maratos E, Smith L, Jackson MJ, Pearce RKB, Jenner P, Marsden CD. Inducing dyskinesias in MPTP-treated common marmosets: the effects of repeated treatment with combinations of L-dopa and ropinirole [Abstract]. Neurology 1998;50(suppl 4):135.
41. Rinne UK. Combined bromocriptine-levodopa therapy early in Parkinson's disease. Neurology 1985;35:196-198.
42. Rascol A, Guiraud B, Montastruc JL, David J, Clanet M. Long-term treatment of Parkinson's disease with bromocriptine. J Neurol Neurosurg Psychiatry 1979;42:143-150.
43. Lees AJ, Stern GM. Sustained bromocriptine therapy in previously untreated patients with Parkinson's disease. J Neurol Neursurg Psychiatry 1981;44:1020-1023.
44. Montastruc JL, Rascol O, Senard JM, Rascol A. A randomized controlled study of bromocriptine versus levodopa in previously untreated parkinsonian patients: a 3-year follow-up. J Neurol Neurosurg Psychiatry 1989;52:773-775.
45. Gagnon C, Bédard PJ, Di Paolo T. Effect of chronic treatment of MPTP monkeys with dopamine D1 and/or D2 receptor agonists. Eur J Pharmacol 1990;178:15-120.
46. Falardeau P, Bouchard S, Bédard PJ, Boucher R, Di Paolo T. Behavioral and biochemical effect of chronic treatment with D1 and/or D2 dopamine agonists in MPTP monkeys. Eur J Pharmacol 1988;150:59-66.
47. Pearce RKB, Banerji T, Jenner P, Marsden CD. De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset. Mov Disord 1998; 13:234-241.
48. Quinn NP, Lang AE, Thompson C, Brincart S, Marsden CD, Parkes JD. Pergolide in the treatment of Parkinson's disease. Adv Neurol 1984;40:509-513.
49. Grondin R, Goulet M, Di Paolo T, Bédard PJ. Cabergoline, a long acting dopamine D2-like receptor agonist, produces a sustained antiparkinsonian effect with transient dyskinesias in parkinsonian drug-naive primates. Brain Res 1996;735:298-306.
50. Gomez-Mancilla B, Bédard PJ. Effects of D1 and D2 agonists and antagonists on dyskinesia produced by L-dopa in MPTP monkeys. J Pharmacol Exp Ther 1991;259:409-413.
51. Goetz CG, Tanner CM, Klawans HL. Drug holiday in the management of Parkinson's disease. Clin Neuropharmacol 1982;5: 351-364.
52. Weiner WJ, Koller WC, Perlik S, Nansieda PA, Klawans HL. Drug holiday and management of Parkinson's disease. Neurology 1980;30:1257-1261.
53. Friedman JH. 'Drug holidays' in the treatment of Parkinson's disease. A brief review. Arch Intern Med 1985;145:913-915.
54. Agid Y. Levodopa. Is toxicity a myth? Neurology 1998;50:858-863.
55. Defer GL, Geny C, Ricolfi F, et al. Long-term outcome of unilaterally transplanted parkinsonian patients. Clinical approach. Brain 1996;119:41-50.
56. Lopez-Lozano JJ, Bravo G, Brera B, et al. Long-term improvement in patients with severe Parkinson's disease after implantation of fetal ventral mesencephalic tissue in a cavity of the caudate nucleus: 5-year follow up in 10 patients. J Neurosurg 1997; 86:931-942.
57. Colzi A, Turner K, Lees AJ. Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease. J Neurol Neurosurg Psychiatry 1998;64:573-576.
58. Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. Ann Neurol 1993;328:176-183.
59. Parkinson Study Group. Impact of deprenyl and tocopherol treatment in Parkinson's disease in DATATOP patients requiring levodopa. Ann Neurol 1996;39:37-45.
60. Nutt JG, Holford NHG. The response to levodopa in Parkinson's disease: imposing pharmacological law and order. Ann Neurol 1996;39:561-573.
61. Nutt JG, Carter JH, Woodward WR. Longduration response to levodopa. Neurology 1995;45:1613-1616.
62. Mouradian MM, Heuser IJE, Baronti F, Fabbrini G, Juncos JL, Chase TN. Pathogenesis of dyskinesias in Parkinson's disease. Ann Neurol 1989;25:523-526.
63. Schuh LA, Bennett JP. Suppression of dyskinesias in advanced Parkinson's disease: continuous intravenous levodopa shifts dose response for production of dyskinesias but not for relief of parkinsonism in patients with advanced Parkinson's disease. Neurology 1993;43:1545-1550.
64. Durif F, Vidailhet M, Assal F, Roche C, Bonnet AM, Agid Y. Low-dose clozapine improves dyskinesias in Parkinson's disease. Neurology 1997;48:658-662.
65. Bennett JP, Landow ER, Schuh LA. Suppression of dyskinesias in advanced Parkinson's disease: increasing daily clozapine doses suppress dyskinesias and improve parkinsonism symptoms. Neurology 1993;43:1551-1555,
66. Bennett JP, Landow ER, Dietrich S, Schuh LA. Suppression of dyskinesia in advanced Parkinson's disease: moderate daily clozapine dose provides long-term dyskinesia reduction. Mov Disord 1994;9:409-414.
67. Verhagen Metman L, Del Dotto P, van den Munckhof P, Fang J, Mouradian MM, Chase TN. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Neurology 1998;50:1323-1326.
68. Lang AE, Lozano AM, Montgomery E, Duff J, Tasker R, Hutchinson W. Posteroventral medial pallidotomy in advanced Parkinson's disease. N Engl J Med 1997;337:1036-1042.
69. Fabbrini G, Juncos J, Mouradian MM, Serrati C, Chase TN. Levodopa pharmacokinetic mechanisms and motor fluctuations in Parkinson's disease. Ann Neurol 1987;21:370-376.
70. Nutt JG. Pharmacokinetics and pharmacodynamics of levodopa. Clinical implications. In: Koller WC, ed. Handbook of Parkinson's Disease. New York, NY: Marcel Dekker, 1992:411-431.
71. Verhagen Metman LV, Locatelli ER, Bravi D, Mouradian MM, Chase TN. Apomorphine responses in Parkinson's disease and the pathogenesis of motor complications. Neurology 1997;48: 369-372.
72. Engber TM, Susel Z, Juncos J, Chase T. Continuous and intermittent levodopa differentially affect rotation induced by D1 and D2 dopamine agonists. Eur J Pharmacol 1989;168:291-298.
73. Juncos JL, Engber TM, Raisman R, Chase TN. Continuous and intermittent levodopa differentially affect basal ganglia function. Ann Neurol 1989;25:473-478.
74. Mouradian MM, Heuser IJE, Baronti F, Chase TN. Modification of central dopaminergic mechanism by continuous levodopa therapy for advanced Parkinson's disease. Ann Neurol 1990;27: 18-23.
75. Block G, Liss C, Reines S, Irr J, Nibbelink D. Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease. A multicentre 5-year study. The CR First Study Group. Eur Neurol 1997;37:23-27.
76. Poewe W, Kleedorfer B, Wagner M, Büsch S, Schelosky L. Continuous subcutaneous apomorphine infusions for fluctuating Parkinson's disease. Long-term follow-up in 18 patients. In: Narabayashi H, Nagatsu T, Yanagisawa N, Mizuno Y, eds. Advances in Neurology, vol 60. New York, NY: Raven Press, 1993:656-659.
77. Baronti F, Mouradian MM, Davis TL, et al. Continuous lisuride effects on central dopaminergic mechanisms in Parkinson's disease. Ann Neurol 1992;32:776-781.
78. Goulet M, Grondin R, Blanchet PJ, Bédard PJ, Di Paolo T. Dyskinesias and tolerance induced by chronic treatment with a D1 agonist administered in pulsatile or continuous mode do not correlate with changes of putaminal D1 receptors in drug-naive MPTP monkeys. Brain Res 1996;719:129-137.
79. Asin KE, Wirtshafter D. Effects of repeated dopamine D1 receptor stimulation on rotation and c-fos expression. Eur J Pharmacol 1993;235:167-168.
80. Cedarbaum JM, Silvestri M, Kutt H. Sustained enterai administration of levodopa increases and interrupted infusion decreases levodopa dose requirements. Neurology 1990;40:995-997.
81. Obeso JA, Grandas F, Herrero MT, Horowski R. The role of pulsatile versus continuous dopamine receptor stimulation for functional recovery in Parkinson's disease. Eur J Neurosci 1994; 6:889-897.
82. Neve KA, Neve RL. Molecular biology of dopamine receptors. In: Neve KA, Neve RL, eds. The Dopamine Receptors. Totowa, NJ: Humana Press Inc, 1997:27-76.
83. Schwartz JC, Giros B, Martres MP, Sokoloff P. The dopamine receptor family: molecular biology and pharmacology. The Neurosciences 1992;4:99-108.
84. Grefen CR, Keefe KA. Neostriatal dopamine receptors. Trends Neurosci 1994;17:2-3.
85. Tarsy D, Parkes JD, Marsden CD. Metoclopramide and pimozide in Parkinson's disease and levodopa-induced dyskinesias. J Neurol Neurosurg Psychiatry 1975;38:331-335.
86. Klawans HL, Weiner WJ. Attempted use of haloperidol in the treatment of L-dopa-induced dyskinesias. J Neurol Neurosurg Psychiatry 1974;37:427-430.
87. Ekesbo A, Andren PE, Gunne LM, Tedrof J. (-)-OSU6162 inhibits levodopa-induced dyskinesias in a monkey model of Parkinson's disease. Neuroreport 1997;8:2567-2570.
88. Guttman M, Seeman P. L-Dopa reverses the elevated density of D2 dopamine receptors in Parkinson's disease striatum. J Neural Transm 1985;64:93-103.
89. Sawle GV, Brooks DJ, Ibanez V, Frackowiack RST. Striatal D2 receptor density is inversely proportional to dopa uptake in treated hemiparkinson's disease: a PET study [Letter]. J Neurol Neurosurg Psychiatry 1990;53:177.
90. Rioux L, Frohna PA, Joyce JN, Schneider JS. The effects of chronic levodopa treatment on pre- and post-synaptic markers of dopaminergic function in striatum of parkinsonian monkeys. Mov Disord 1997;12:148-158.
91. Turjanski N, Lees AJ, Brooks DJ. In vivo studies on striatal dopamine D1 and D2 site binding in L-dopa-treated Parkinson's disease patients with and without dyskinesias. Neurology 1997; 49:717-723.
92. Brücke T, Bankeiwicz K, Harvey-White J, Kopin I. The partial dopamine agonist terguride in the MPTP-induced hemiparkinsonian monkey model. Eur J Pharmacol 1988;148:445-448.
93. Corsini GU, Bonucelli U, Rainer E, Del Zompo M. Therapeutic efficacy of a partial dopamine agonist in drug-free parkinsonian patients. J Neural Transm 1985;64:105-111.
94. Tetsuo A, Yamaguchi M, Mizuta E, Kunos S. Effects of terguride, a partial D2 agonist, on MPTP-lesioned parkinsonian cynomolgus monkeys. Ann Neurol 1993;33:507-511.
95. Baronti F, Mouradian MM, Conant KE, Giuffra M, Brughitta G, Chase TN. Partial dopamine agonist therapy of levodopa-induced dyskinesias. Neurology 1992;42:1241-1243.
96. Critchley P, Parkes D. Transdihydrolisuride in parkinsonism. Clin Neuropharmacol 1987;10:57-64.
97. Murray AM, Waddington JL. The interaction of clozapine with dopamine D1 versus D2 receptor-mediated function: behavioural indices. Eur J Pharmacol 1990;186:79-86.
98. Blanchet PJ, Gomez-Mancilla B, Bédard PJ. Dopa-induced 'peak dose' dyskinesia: clues implicating D2 receptor-mediated mechanisms using dopaminergic agonists in MPTP monkeys. J Neurol Transm 1995;45(suppl): 103-112.
99. Braun A, Mouradian MM, Mohr E, Fabbrini G, Chase TN. Selective D1 dopamine receptor agonist effects in hyperkinetic extrapyramidal disorders. J Neurol Neurosurg Psychiatry 1989;52: 631-635.
100. Emre M, Rinne UK, Rascol A, Lees A, Agid Y, Lataste X. Effects of a selective partial D1 agonist, CY 208-243, in de novo patients with Parkinson's disease. Mov Disord 1992;7:239-243.
101. Rascol O, Blin O, Descombes S, et al. ABT-431, a selective D1 agonist has efficacy in patients with Parkinson's disease. Neurology 1997;48:269-270.
102. Levant B. The D3 dopamine receptor: neurobiology and potential clinical relevance. Pharmacol Rev 1997;49:231-252.
103. Bordet R, Kidray S, Carboni S, Diaz J, Sokoloff P, Schwartz JC. Induction of dopamine D3 receptor expression as a mechanism of behavioral sensitization to levodopa. Proc Natl Acad Sci USA 1997;94:3363-3367.
104. Blanchet PJ, Konitsiotis S, Chase T. Motor response to a dopamine D3 receptor preferring agonist compared to apomorphine in levodopa-primed MPTP monkeys. J Pharmacol Exp Ther 1997; 283:794-799.
105. Jenner P, Tulloch I. The preclinical pharmacology of ropinirolereceptor interactions, antiparkinsonian activity and potential to induce dyskinesia. In: Olanow W, Obeso JA, eds. Beyond the Decade of the Brain, Vol 2: Dopamine Agonists in Early Parkinson's Disease. Royal Tunbridge Kells, UK: Wells Medical Limited, 1997:115-128.
106. Gallick Whitaker NG, Lindstron TD. Disposition and biotransformation of quinpirole, a new D-2 dopamine agonist antihypertensive agent, in mice, rats, dogs and monkeys. Drug Metab Dispos 1987;15:107-113.
107. Bédard PJ, Gomez-Mancilla B, Blanchette P, Gagnon C, Falardeau P, DiPaolo T. Role of selective D1 and D2 agonists in inducing dyskinesia in drug-naive MPTP monkeys. Adv Neurol 1993;60:113-118.
108. Engber TM, Susel Z, Kuo S, Gerfen CR, Chase TN. Levodopa replacement therapy alters enzymes' activities in striatum and neuropeptide content in striatal output regions of 60H lesioned rats. Brain Res 1991;552:113-118.
109. Engber TM, Boldry RC, Kuo S, Chase TN. Dopaminergic modulation of striatal neuropeptides: differential effects of D1 and D2 receptor stimulation on somatostatin, neuropeptide Y, neurotensin, dymorphin and enkephalin. Brain Res 1992;581:261-268.
110. Grefen CR, Engber TM, Mahan LC, et al. D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science 1990;250:1429-1432.
111. Engber TM, Papa SM, Boldry RC, Chase TN. NMDA receptor blockade reverses motor response alterations induced by levodopa. Neuroreport 1994;5:2586-2588.
112. Clarke CE, Boyce S, Robertson RG, Sambrook MA, Crossman AR. Drug-induced dyskinesia in primates rendered hemiparkinsonian by intracarotid administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). J Neurol Sci 1989;90:307-314.
113. Gomez-Mancilla B, Bédard PJ. Effect of nondopaminergic drugs on L-dopa-induced dyskinesias in MPTP-treated monkeys. Clin Neuropharmacol 1993;16:418-427.
114. Papa SM, Chase TN. Levodopa-induced dyskinesias improved by a glutamate antagonist in parkinsonian monkeys. Ann Neurol 1996;39:574-578.
115. Kornhuber J, Bormann J, Hubers M, Rusche K, Riederer P. Effects of the 1-amino-adamantanes at the MK-801-binging site of the NMDA-receptor-gated ion channel: a human post-mortem brain study. Eur J Pharmacol 1991;206:297-300.
116. Kornhuber J, Quack G, Danysz W. Therapeutic brain concentration of the NMDA receptor antagonist amantadine. Neuropharmacology 1995;35:713-721.
117. Rajput AH, Ryan JU, Lang AE, Rajput AH, Kumar R, Galvez-Jimenez N. Amantadine ameliorates levodopa induced dyskinesia [Letter]. Neurology 1997;48:328.
118. Montastruc JL, Rascol O, Senard JM. Glutamate antagonists and Parkinson's disease: a review of clinical data. Neurosci Biobehav Rev 1997;21:477-480.
119. Verhagen Metman L, Blanchet PJ, van den Munckhof P, Del Dotto P, Natte R, Chase TN. A trial of dextromethorphan in parkinsonian patients with motor response complications. Mov Disord 1998;13:414-417.
120. Verhagen Metman L, Del Dotto P, Natte R, van den Munckhof P, Chase TN. Dextromethorphan improves levodopa-induced dyskinesias in Parkinson's disease. Neurology 1998;51:203-206.
121. Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V, for the Amyotrophic Lateral-Sclerosis/Riluzole Study Group II. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Lancet 1996;347:1425-1431.
122. Bryson HM, Fulton B, Benfield P. Riluzole: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in amyotrophic lateral sclerosis. Drugs 1996;52:549-563.
123. Dray A, Davies J, Oakley NR, Tongroach P, Vellucci S. The dorsal and medial raphe projections to the substantia nigra in the rat: electrophysiological, biochemical and behavioral observations. Brain Res 1978;151:431-432.
124. Costall B, Fortune DH, Naylor RJ, Marsden CD, Pycock C. Serotonergic involvement with neuroleptic catalepsy. Neuropharmacology 1975;14:859-868.
125. Mengod G, Nguyen H, Le H, Waeber C, Lubbert H, Palacios JM. The distribution and cellular localization of the serotonin IC receptor mRNA in the rodent brain examined by in situ hybridization histochemistry: comparison with receptor binding distribution. Neuroscience 1990;35:577-591.
126. Pazos A, Probst A, Palacios JM. Serotonin receptors in the human brain. III: autoradiographic mapping of serotonin-1 receptors. Neuroscience 1987;21:97-122.
127. Fox SM, Moser B, Brotchie JM. Behavioral effects of 5HT2c receptor antagonism in the substantia nigra zona reticulata of the 6-hydroxy dopamine-lesioned rat model of Parkinson's disease. Exp Neurol 1998;151:35-49.
128. Meco G, Marini S, Lestingi L, Linfante I, Modarelli FT, Agnoli A. Controlled single-blind cross-over study of ritanserin and placebo in L-dopa-induced dyskinesias in Parkinson's disease. Curr Ther Res 1988;43:262-270.
129. Durif F, Vidailhet M, Bonnet AM, Blin J, Agid Y. Levodopa-induced dyskinesias are improved by fluoxetine. Neurology 1995; 45:1855-1858.
130. Hoyer D, Clarke DE, Fozard JR, et al. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol Rev 1994;46:157-203.
131. Baldwin D, Fineberg N, Montgomery S. Fluoxetine, fluvoxamine and extrapyramidal tract disorders. Int Clin Psychopharmacol 1991;6:51-58.
132. Ludwig CL, Weinberger DR, Bruno G, et al. Buspirone, Parkinson's disease, and the locus coeruleus. Clin Neuropharmacol 1986;9:373-378.
133. Kleedorfer B, Lees AJ, Stern GM. Buspirone in the treatment of levodopa induced dyskinesias. J Neurol Neurosurg Psychiatry 1991;54:376-377.
134. Bonifati V, Fabrizio E, Cipriani R, Vanacore N, Meco G. Buspirone in levodopa-induced dyskinesias. Clin Neuropharmacol 1994;17:73-82.
135. Hammerstad JP, Carter J, Nutt JG, et al. Buspirone in Parkinson's disease. Clin Neuropharmacol 1986;9:556-560.
136. Henry B, Plowright A, Fox SH, et al. Alpha-2-adrenergic antagonists reduce symptoms in animal models of L-dopa-induced dyskinesias [Abstract]. Soc Neurosci Abst 1997;23:742.
137. Rascol O, Arnulf I, Brefel C, et al. L-Dopa induced dyskinesia improvement by an α2 antagonist, idazoxan, in patients with Parkinson's disease [Abstract]. Mov Disord 1997;12:5111.
138. Brefel-Courbon C, Thalamas C, Peyro Saint Paul H, Senard JM, Montastruc JL, Rascol O. Alpha-2 adrenoceptor antagonists. A new approach to Parkinson's disease? CNS Drugs 1998;10:189-207.
139. Henry B, Brotchie JM. Potential of opioid antagonists in the treatment of levodopa-induced dyskinesias in Parkinson's disease. Drug Aging 1996;9:149-158.
140. Piccini P, Weeks RA, Brooks DJ. Alterations in opioid receptor binding in Parkinson's disease patients with levodopa-induced dyskinesias. Ann Neurol 1997;42:720-726.
141. Newman DD, Rajakumar N, Flumerfelt B, Stoesse AJ. A kappa opioid antagonist blocks sensitization in a rodent model of Parkinson's disease. Neuroreport 1997;8:669-672.
142. Trabucchi M, Bassi S, Frattola L. Effects of naloxone on the 'on-off' syndrome in patients receiving long-term levodopa therapy. Arch Neurol 1982;39:120-121.
143. Sandyk R, Snider SN. Naloxone treatment of L-dopa-induced dyskinesia in Parkinson's disease [Letter]. Am J Psychiatry 1986; 143:118.
144. Nutt JG, Rosin AJ, Eisler T, Calne DB, Chase TN. Effect of an opiate antagonist on movement disorders. Arch Neurol 1978;35: 810-811.
145. Rascol O, Fabre N, Blin O, et al. Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease. Mov Disord 1994;9:437-440.
146. Schiffman SN, Jacobs O, Vanderhaeghen JJ. Striatal restricted adenosine A2 receptor (RD C8) is expressed by enkephalin but not by substance P neurons: an in situ hybridization histochemistry study. J Neurochem 1991;57:1062-1067.
147. Kanda T, Jackson MJ, Smith LA, et al. Adenosine A2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys. Ann Neurol 1998;43:507-513.
148. Carpentier AF, Bonnet AM, Vidailhet M, Agid Y. Improvement of levodopa-induced dyskinesia by propranolol in Parkinson's disease. Neurology 1996;46:1548-1551.
149. Mendez JS, Cotzias GC, Mena I, Papavasiliou PS. Diphenylhydantoine, blocking of levodopa effects. Arch Neurol 1975;32:44-46.
150. Gomez-Mancilla B, Bédard PJ. Effect of oestrogen and progesterone on L-dopa-induced dyskinesias in MPTP-treated monkeys. Neurosci Lett 1992;135:129-132.
151. Bédard P, Langelier P, Villeneuve A. Oestrogens and extrapyramidal system. Lancet 1977;2:1367-1368.
152. Tarsy D, Leopold N, Sax DS. Physostigmine in choreiform movement disorders. Neurology 1974;24:28-33.